ZENECA ZESTRIL BRAND LISINOPRIL OUTSELLING MERCK'S PRINIVIL TWO TO ONE, ZENECA REPORTS; PHARMACEUTICAL SALES IN U.S. DECLINE 2% FROM 1993
Zeneca's Zestril brand of lisinopril is outselling Merck's Prinivil two to one, according to January IMS data, Zeneca Pharmaceuticals President Robert Black said at a press conference March 2 in New York City. Two of every three lisinopril prescriptions were filled with Zestril in January, Black reported. The Zeneca drug's U.S. market share rose from 17.9% to 19%, he added. Zeneca licenses lisinopril from Merck.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth